Patent details

Basic Information

Publication number:

EP2854816

PCT Application Number:

US2013042959

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP137968707

PCT Publication Number:

WO2013181174

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST

French Title of Invention:

FORMULATIONS PHARMACEUTIQUES SOLIDES D'UN ANTAGONISTE DE RÉCEPTEUR D'OREXINE

German Title of Invention:

FESTE DARREICHUNGSFORMULIERUNGEN EINES OREXIN-REZEPTORANTAGONISTEN

SPC Number:

Dates

Filing date:

29/05/2013

Grant date:

08/07/2020

EP Publication Date:

08/04/2015

PCT Publication Date:

05/12/2013

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

08/07/2020

EP B1 Publication Date:

08/07/2020

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

29/05/2021

Expiration date:

29/05/2033

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

01/07/2020

 

 

Name:

Merck Sharp & Dohme Corp.

Address:

126 East Lincoln Avenue, Rahway, NJ 07065-0907, United States (US)

Inventor

1

Name:

HARMON, Paul, A.

Address:

United States (US)

2

Name:

VARIANKAVAL, Narayan

Address:

United States (US)

Priority

1

Priority Number:

201261653539 P

Priority Date:

31/05/2012

Priority Country:

United States (US)

2

Priority Number:

201361787686 P

Priority Date:

15/03/2013

Priority Country:

United States (US)

Classification

IPC classification:

A61K 9/20; A61K 31/551;

Publication

European Patent Bulletin

Issue number:

202028

Publication date:

08/07/2020

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages